TLPH
Talphera·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TLPH
Talphera, Inc.
A specialty pharmaceutical company that develops therapies for acute post-operative pain and cancer breakthrough pain
1850 Gateway Drive, Suite 175, San Mateo, CA 94404
--
Talphera, Inc., was originally registered in Delaware as SuRX, Inc., on July 13, 2005. The company subsequently changed its name to AcelRx Pharmaceuticals, and the company changed its name from "AcelRx Pharmaceuticals, Inc." to "Talphera, Inc." on January 10, 2024. The Company is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for medical regulatory settings. Talphera's lead product candidate, Niyad, a lyophilized formulation of nafamostat, is currently being studied under the Research Device Exemption (IDE) as an anticoagulant for the in vitro circuit and has received Breakthrough Device Designation status from the FDA. Talphera is also developing two pre-filled syringes licensed from partner Aguettant: Fedsyra, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
Earnings Call
Q2/2025
Estimate EPS-0.12
Actual EPS-0.1
Estimate Revenue--
Actual Revenue0
Talphera's 2025 Q2 Earnings Call: Unraveling Key Contradictions in Enrollment Rates and Site Activations
Aug 14,2025 09:19
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
TLPH has released its 2025 Q3 earnings. EPS was reported at -0.11, versus the expected -0.12, beating expectations. The chart below visualizes how TLPH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TLPH has released its 2025 Q3 earnings report, with revenue of 1.00K, reflecting a YoY change of NaN%, and net profit of -4.44M, showing a YoY change of -32.30%. The Sankey diagram below clearly presents TLPH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
